Chris Denison - June 8, 2026

EPO decision T 0655/24: Striking the Right Balance in Antibody Claim Drafting

This is the second in a series of three posts on recent decision T 0655/24 and its implications for ...

Louise Atkins - June 8, 2026

FA Bio: unlocking the secrets of soil microbiome

Forward speaks to Ángela de Manzanos Guinot, founder of FA Bio, about how they are replacing harsh ...

Matthew Naylor - June 8, 2026

UPC Weekly - The long arm workflow and checklist

UPC Weekly brings you timely, thoughtful and joined-up insight into the evolving landscape of ...

Andrew Mears - June 8, 2026

Medical Technologies: From Concept to Patient Care

On Tuesday 3 June 2026, we were delighted to host our in-person panel discussion and networking ...

Joanna Smith - June 5, 2026

Mewburn Ellis recognised in IAM Patent 1000 litigation rankings 2026

We are delighted to share that Mewburn Ellis has now entered the IAM Patent 1000 litigation ...

Anja Koller - June 4, 2026

“AI” in Bioprocessing – What’s Behind the Buzzword?

At the 2026 Global Bioprocessing & Biotechnology Summit in Berlin, “AI” was a hot topic – from ...

Frances Salisbury - June 2, 2026

Daya Ventures: The startup factory closing the gender health gap

Forward speaks to Daya Venture's CCO, Victorine Lançon as she tells Mewburn Ellis why 16 startups ...

Andrew Pitts - June 2, 2026

Orforglipron FDA Approval: Why the First Small-Molecule GLP-1 Pill Matters

The GLP-1 landscape changed on 1 April 2026, when the FDA approved Eli Lilly's orforglipron under ...